Whether or not the Meanses are granted their wishlist, they stand to profit when people buy into “MAHA.” The siblings regularly mention their best-selling book and their companies.
Levels, the company Casey co-founded, is riding a wave of booming interest in continuous glucose monitoring (CGM). The company has raised nearly $100 million in venture capital funding in three years. It reportedly has more than 20,000 members who pay $199 annually for basic functions, or another $199 per month for connection with a CGM. (Levels is not covered by insurance.) And the recent
availability of over-the-counter CGMs could open the door to bio-monitoring for the masses, even as questions remain about who the devices are appropriate for beyond those with type 1 diabetes.
The drive for more personal biomedical information is a constant in the Meanses’ talks. Standard blood tests and an annual physical aren’t enough. They say Americans should know all they can about their biomarkers in order to spot potential diseases and avoid medication. They often mention Mark Hyman, a physician, author and media personality who sells extensive lab tests for $500 through his company, Function Health. Once people know what’s going on in their blood, they can address it with food and exercise, they say.